Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA RCC-208: Pumitamig with Ipilimumab or Cabozantinib in Advanced Renal Cell Carcinoma
jRCT2031260081Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of pumitamig in renal cell carcinoma (RCC) (10 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants with adverse events, Number of participants with serious adverse events and 4 more. Started Jun 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2031260081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260081.